Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.31 EX-10.31
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 10.50 EX-10.50
- 10.51 EX-10.51
- 10.52 EX-10.52
- 10.53 EX-10.53
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.7 EX-99.7
- Download Excel data file
- View Excel data file
Associated filings
- 13 Jul 23 424B3 Prospectus supplement
- 3 Jul 23 424B3 Prospectus supplement
- 7 Jun 23 EFFECT Notice of effectiveness
- 6 Jun 23 424B3 Prospectus supplement
-
2 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Apr 23 S-4 Registration of securities issued in business combination transactions
MEIP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
MEI Pharma, Inc.
San Diego, California
We hereby consent to the use in the joint proxy statement/prospectus constituting a part of this Registration Statement of our report dated September 8, 2022, except for the impact of the reverse stock split described in Note 1, as to which the date is April 27, 2023, relating to the financial statements of MEI Pharma, Inc., which is contained in that joint proxy statement/prospectus.
We also consent to the reference to us under the caption “Experts” in the joint proxy statement/prospectus.
/s/ BDO USA, LLP
San Diego, California
June 2, 2023